… Prof Luca Richeldi, MD Luca Richeldi … Correspondence to: Prof Luca Richeldi, Unità Operativa
Complessa di Pneumologia, Università Cattolica del Sacro Cuore, Fondazione Policlinico …

Acute exacerbation of idiopathic pulmonary fibrosis has been defined as an acute, clinically
significant, respiratory deterioration of unidentifiable cause. The objective of this …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized by
progressive lung scarring and the histological picture of usual interstitial pneumonia (UIP). It is …

This document is an international evidence-based guideline on the diagnosis and management
of idiopathic pulmonary fibrosis, and is a collaborative effort of the American Thoracic …

Background Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that
targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of …

With more than 900 000 confirmed cases worldwide and nearly 50 000 deaths during the
first 3 months of 2020, the coronavirus disease 2019 (COVID-19) pandemic has emerged as …

This Review provides an updated approach to the diagnosis of idiopathic pulmonary fibrosis
(IPF), based on a systematic search of the medical literature and the expert opinion of …

Background: In 2002 the American Thoracic Society/European Respiratory Society (ATS/ERS)
classification of idiopathic interstitial pneumonias (IIPs) defined seven specific entities, …

Background: This document provides clinical recommendations for the diagnosis of
idiopathic pulmonary fibrosis (IPF). It represents a collaborative effort between the American …

… Luca Richeldi … Luca Richeldi … Raghu G, Wells AU, Nicholson AG, Richeldi L, Flaherty KR,
Le Maulf F, et al. Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic …